Michael L. Jackson, PhD, MPH

Jackson_Michael_L_205x293.jpg

“I study the benefits of vaccines and the impact that vaccination programs can have on protecting communities from infectious diseases. I aim to help people make informed decisions about immunizations for themselves and their children.”

Michael L. Jackson, PhD, MPH

Senior Investigator, Kaiser Permanente Washington Health Research Institute

Biography

Michael L. Jackson, PhD, MPH, focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Kaiser Permanente Washington Health Research Institute (KPWHRI) principal investigator for the United States Influenza Vaccine Effectiveness (US Flu VE) Network. Using information from five sites across the country, including Kaiser Permanente Washington, this network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies.

In addition, Dr. Jackson is using data collected by the US Flu VE Network to build a simulation model for the spread of influenza, with a specific focus on understanding when new strains of the influenza virus can out-compete existing strains. This work, funded by the National Institutes of Health, aims to improve our ability to correctly choose which strains of the influenza virus to include in seasonal influenza vaccines. He also uses simulation models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenzae type b (Hib) and Neisseria meningitidis.

Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the safety of childhood immunizations and develops methods for using managed care data for vaccine safety studies.

While studying for his PhD at the University of Washington, Dr. Jackson was a graduate research associate with KPWHRI from 2002 to 2007, and then a postdoctoral fellow at KPWHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to KPWHRI as an assistant investigator in 2010. He is an affiliate associate professor at the University of Washington School of Public Health.

Research interests and experience

Recent publications

Wu MJ, Chung JR, Kim SS, Jackson ML, Jackson LA, Belongia EA, McLean HQ, Gaglani M, Reis M, Beeram M, Martin ET, Monto AS, Nowalk MP, Zimmerman R, Santibanez TA, Singleton JA, Patel M, Flannery B. Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011-2012 through 2018-2019. Vaccine. 2021 Feb 15:S0264-410X(21)00106-7. doi: 10.1016/j.vaccine.2021.01.065. [Epub ahead of print]. PubMed

Li X, Mukandavire C, Cucunubá ZM, Echeverria Londono S, Abbas K, Clapham HE, Jit M, Johnson HL, Papadopoulos T, Vynnycky E, Brisson M, Carter ED, Clark A, de Villiers MJ, Eilertson K, Ferrari MJ, Gamkrelidze I, Gaythorpe KAM, Grassly NC, Hallett TB, Hinsley W, Jackson ML, Jean K, Karachaliou A, Klepac P, Lessler J, Li X, Moore SM, Nayagam S, Nguyen DM, Razavi H, Razavi-Shearer D, Resch S, Sanderson C, Sweet S, Sy S, Tam Y, Tanvir H, Tran QM, Trotter CL, Truelove S, van Zandvoort K, Verguet S, Walker N, Winter A, Woodruff K, Ferguson NM, Garske T; Vaccine Impact Modelling Consortium. Estimating the health impact of vaccination against 10 pathogens in 98 low and middle income countries from 2000 to 2030. Lancet. 2021 Jan 30;397(10272):398-408. doi: 10.1016/S0140-6736(20)32657-X. PubMed

McCulloch DJ, Jackson ML, Hughes JP, Lester S, Mills L, Freeman B, Rasheed MAU, Thornburg NJ, Chu HY. Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020. PLoS One. 2021 May 27;16(5):e0252235. doi: 10.1371/journal.pone.0252235. eCollection 2021. PubMed

Tenforde MW, Kondor RJG, Chung JR, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Rao A, Kim SS, Stark TJ, Barnes JR, Wentworth D, Patel MM, Flannery B. Effect of antigenic drift on influenza vaccine effectiveness in the United States - 2019-2020. Clin Infect Dis. 2020 Dec 25:ciaa1884. doi: 10.1093/cid/ciaa1884. Online ahead of print. PubMed

Chung JR, Kim SS, Jackson ML, Jackson LA, Belongia EA, King JP, Zimmerman RK, Nowalk MP, Martin ET, Monto AS, Gaglani M, Smith ME, Patel M, Flannery B. Clinical symptoms among ambulatory patients tested for SARS-CoV-2. Open Forum Infect Dis. 2020 Nov 26;8(1):ofaa576. doi: 10.1093/ofid/ofaa576. eCollection 2021. PubMed

Newman KL, Rogers JH, McCulloch D, Wilcox N, Englund JA, Boeckh M, Uyeki TM, Jackson ML, Starita L, Hughes JP, Chu HY, Seattle Flu Study Investigators. Point-of-care molecular testing and antiviral treatment of influenza in residents of homeless shelters in Seattle, WA: study protocol for a stepped-wedge cluster-randomized controlled trial. Trials. 2020 Nov 23;21(1):956. doi: 10.1186/s13063-020-04871-5. PubMed

Emanuels A, Heimonen J, O’Hanlon J, Kim AE, Wilcox N, McCulloch DJ, Brandstetter E, Wolf CR, Logue JK, Han PD, Pfau B, Newman KL, Hughes JP, Jackson ML. Remote household observation for non-influenza respiratory viral illness. Clin Infect Dis. 2020 Nov 17:ciaa1719. doi: 10.1093/cid/ciaa1719. PubMed

Patel MM, Jackson ML, Ferdinands J. Postlicensure evaluation of COVID-19 vaccines. JAMA. 2020 Nov 17;324(19):1939-1940. doi: 10.1001/jama.2020.19328. PubMed

Greene DN, Jackson ML, Hillyard DR, Delgado JC, Schmidt RL. Decreasing median age of COVID-19 cases in the United States-changing epidemiology or changing surveillance? PLoS One. 2020 Oct 15;15(10):e0240783. doi: 10.1371/journal.pone.0240783. eCollection 2020. PubMed

Jackson ML. Low-impact social distancing interventions to mitigate local epidemics of SARS-CoV-2. Microbes Infect. 2020 Sep 22:S1286-4579(20)30159-3. doi: 10.1016/j.micinf.2020.09.006. [Epub ahead of print]. PubMed

 

Research

Chart showing lives saved with vaccination for 10 pathogens

The impact of vaccines: Millions of lives saved

Vaccines given in last 20 years could prevent 50 million deaths in 112 countries

Healthy findings blog

Flu Season illustration young woman looking at phone screen mask and virus illustrations

COVID-19 and flu: What to expect this winter

Answers to 4 questions about COVID-19 and this season's flu, from KPWHRI's Michael Jackson, PhD, MPH.

Healthy Findings Blog

COVID-MJACKSON-blog_1col.jpg

The next stage in COVID-19 vaccine research

In a JAMA Viewpoint, Dr. Mike Jackson plans ahead to meet the challenges of continuing to evaluate new vaccines.

KPWHRI In the Media

Does COVID-19 affect the flu season?

Flu rates plummet in the midst of COVID-19 pandemic

Verywell Health, Jan. 13, 2021

Influenza

Mike-Jackson-flu-vaccines_1col.jpg

Flu shot Q & A: Does COVID-19 change our approach?

KPWHRI’s Michael L. Jackson, PhD, MPH, talks about influenza vaccine research in the age of the pandemic.

KPWHRI In the Media

Flu shot Q & A: Does COVID-19 change our approach?

How effective is the flu vaccine?

WebMD, Sept. 2, 2020